newsfilter
← Latest News
GlobeNewswire·

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

RNXT
  • RenovoRx, Inc. (NASDAQ: RNXT) announced its second quarter 2026 financial results conference call will occur on August 12, 2026, at 4:30 p.m. ET.
  • Management will discuss growing revenues from commercial sales of the FDA-cleared RenovoCath device, increased adoption at high-volume U.S. cancer centers, & broader repeat orders from existing customers.
  • An update on the Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine via RenovoCath for locally advanced pancreatic cancer will be provided, with full enrollment expected soon & final data anticipated in mid-to-late 2027.
  • RenovoRx continues to expand its TAMP™ therapy platform, having recently secured FDA Orphan Drug Designation for oxaliplatin in pancreatic cancer, alongside ongoing investigator-initiated trials & a post-marketing registry study.
  • For the first full year of commercial efforts in 2025, RenovoRx generated approximately $1.1 million in RenovoCath sales, with record sales of $563,000 reported in the first quarter of 2026.
  • The IAG combination product candidate is under investigation by the FDA under a 21 CFR 312 pathway & has received Orphan Drug Designation for pancreatic & bile duct cancers, granting seven years of market exclusivity upon approval.
  • The company will host the live call via dial-in numbers 1-877-407-4018 (U.S.) or 1-201-689-8471 (International), with a webcast available at its Investor Relations website.
  • A dial-in replay will be accessible until August 26, 2026, by calling 1-844-512-2921 (U.S.) or 1-412-317-6671 (International) using pin number 13761368.
  • The press release includes a cautionary note regarding forward-looking statements related to clinical trials, regulatory approvals, commercialization efforts, & financial projections.